Ingenia Therapeutics Gets FDA Clearance for IGT-303 Phase 1/2a Trial

Bitget2026/10/27 05:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ingenia Therapeutics can begin its U.S. Phase 1/2a trial of IGT-303 effective Oct. 27, 2026, following the FDA’s 30-day review period.
No FDA objection was received for the study in healthy volunteers and participants with chronic kidney disease.
The trial targets 94 participants, with completion expected April 30, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ingenia Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261027900209), on October 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.

华尔街见闻•2026/11/08 12:41